In TCGA cohort, higher TMB was observed in patients with SETD2 mutant cancer (median, 5.9; interquartile range, 1.8–29.2) than those in patients with SETD2 nonmutant disease (1.5, 0.7–3.3; P < 0.0001). This evidence concerns the gene SETD2 and cancer.